MYRIAD GENETICS INC

For the period ended Dec 31, 2024. Filed Feb 28, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Feb 28, 2025

MYGN$5.67-1.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets as of and

Consolidated Balance Sheets

(in millions, except per share amounts)

	December 31,
	2024	2023
ASSETS
Current assets:
Cash and cash equivalents	$102.4	$132.1
Marketable investment securities	—	8.8
Trade accounts receivable	121.2	114.3
Inventory	27.5	22.0
Prepaid taxes	16.4	17.0
Prepaid expenses and other current assets	30.5	19.4
Total current assets	298.0	313.6
Operating lease right-of-use assets	55.0	61.6
Property, plant and equipment, net	117.4	119.0
Intangibles, net	262.4	349.5
Goodwill	286.3	287.4
Other assets	8.5	15.4
Total assets	$1,027.6	$1,146.5
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$32.3	$25.8
Accrued liabilities	119.0	113.9
Current maturities of operating lease liabilities	12.8	16.2
Total current liabilities	164.1	155.9
Unrecognized tax benefits	32.7	30.2
Long-term debt	39.6	38.5
Noncurrent operating lease liabilities	87.9	97.4
Other long-term liabilities	2.2	41.3
Total liabilities	326.5	363.3
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.01 par value, 91.3 and 89.9 shares outstanding at December 31, 2024 and 2023, respectively	0.9	0.9
Additional paid-in capital	1,457.8	1,415.5
Accumulated other comprehensive loss	(0.8)	(3.7)
Accumulated deficit	(756.8)	(629.5)
Total stockholders' equity	701.1	783.2
Total liabilities and stockholders’ equity	$1,027.6	$1,146.5

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.